



## **Final Appraisal Recommendation**

**Advice No: 0713 – March 2013**

**Glycopyrronium bromide (Seebri® Breezhaler®)  
44 micrograms inhalation powder as hard capsules**

**Submission by Novartis Pharmaceuticals UK Ltd**

### **Recommendation of the All Wales Medicines Strategy Group**

**Glycopyrronium bromide (Seebri® Breezhaler®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1455), which includes the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

**Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:**

**All Wales Medicines Strategy Group. Final Appraisal Recommendation -  
0713: Glycopyrronium bromide (Seebri® Breezhaler®) March 2013.**